IBI-10090

Icon Bioscience Reports Successful Outcomes of Phase 3 Study of IBI-10090, a Novel Sustained Release Drug Being Developed to Treat Inflammation Associated with Cataract Surgery
Yahoo
Mon, 04/6/15 - 10:09 am
ICON
IBI-10090
cataract surgery